Showing results (121-130 of 187) with videos related to

Sort By:
Pageof 19
The Journal of Rheumatology|July 26, 2002
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formationJohannes Grisar, Peter M Bernecker, Martin Aringer, et al.
Annals of Hematology|January 12, 2024
VEXAS syndrome: complete molecular remission after hypomethylating therapyKatja Sockel, Katharina Götze, Christina Ganster, et al.
Zeitschrift Fur Rheumatologie|June 6, 2023
[With RheMIT rheumatology centers can participate in the German national database-Expansion of the long-term rheumatological documentation]Johanna Callhoff, Martin Feuchtenberger, Kirsten Karberg, et al.
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Rheumatology (Oxford, England)|November 11, 2025
Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Eric F Morand, Richard Furie, Martin Aringer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 5, 2018
Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell ProfilingMichelle P Ashton, Anne Eugster, Sevina Dietz, et al.
Arthritis Care & Research|July 26, 2018
Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young AdulthoodKirsten Minden, Gerd Horneff, Martina Niewerth, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Clinical and Experimental Rheumatology|July 15, 2020
ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritisChristof Specker, Annette Alberding, Martin Aringer, et al.
Rheumatology (Oxford, England)|July 9, 2025
Type I interferon limits interleukin-6 signaling in SLE through shedding interleukin-6 receptors]Martyna Hempel, Erik Klapproth, Annika Krause, et al.
Pageof 19